Inventor · disambiguated record
Bjorn L. Millard
Also filed as: MILLARD BJORN L
5 granted patents·2 pending applications·13 citations·filing 2016–2024
76Inventor score
Top patents by PatentIndex Score
7 records- 0190US11155593B2Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5SILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Oct 26, 2021·3 cites·12 claims
- 0286US10040840B2Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissueSILVER CREEK PHARMACEUTICALS INC·Filed 2016·Granted Aug 7, 2018·6 cites·20 claims
- 0386US2025145682A1Compositions and methods of treating tissue damageSILVER CREEK PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0484US10633425B2Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5SILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Apr 28, 2020·4 cites·6 claims
- 0578US12122819B2Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variantSILVER CREEK PHARMACEUTICALS INC·Filed 2022·Granted Oct 22, 2024·0 cites·14 claims
- 0676US11879002B2Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereofSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Jan 23, 2024·0 cites·19 claims
- 0750US2021020264A1Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjectsCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bjorn L. Millard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →